{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:01:07Z","timestamp":1784916067246,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment value is traditionally assessed through clinical benefits, health-related quality of life, and healthcare utilization. However, rare diseases such as generalized myasthenia gravis (gMG) that heavily affect families and\/or caregivers require a more holistic approach that centers around impacted individuals across all areas of daily life. Here, key domains impacted by gMG were identified through individual interviews with both patients and caregivers and these impacts were further assessed through a survey in an independent sample.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Interviews with patients with gMG and caregivers identified 25 patient-centered \u201cimpact elements\u201d across 8 life domains (occupation, financial, emotional, physical, sleep, social, planning and autonomy, and safety). Independently recruited patients and caregivers who completed a subsequent electronic, quantitative survey rated the relevance of impact elements on a scale of 1 (lowest) to 5 (highest).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Respondents included 239 patients with gMG (63%, aged 18\u201349 y; 69%, female) and 81 caregivers (58%, aged 18\u201349 y; 42% female). The 5 domains most impacted by gMG were occupational (mean domain score [SD]: 4.0 [1.2]), planning and autonomy (4.0 [1.1]), financial (3.9 [1.2]), physical (3.9 [1.1]), and sleep (3.9 [1.2]) for patients and financial (3.7 [1.2]), sleep (3.7 [1.1]), occupational (3.6 [1.2]), planning and autonomy (3.6 [1.1]), and safety (3.6 [1.1]) for caregivers. Numerically higher impact scores were observed among patients with more severe disease, younger patients, and caregivers who were unemployed, retired, or disabled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings provide additional insight into the comprehensive burden of gMG that extends beyond symptoms and medical costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01124-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:04:22Z","timestamp":1782234262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterizing and quantifying disease impacts of generalized myasthenia gravis (gMG) in the United States: insights from patient and caregiver interviews and surveys"],"prefix":"10.1186","volume":"10","author":[{"given":"Pushpa","family":"Narayanaswami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"dosReis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Foss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayvis","family":"Rebeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naila","family":"Wahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis C.","family":"Garduno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Crevier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly G.","family":"Gwathmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"5","key":"1124_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475\u2013490. https:\/\/doi.org\/10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"issue":"1","key":"1124_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P et al (2021) Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med 19(1):516. https:\/\/doi.org\/10.1186\/s12967-021-03185-7","journal-title":"J Transl Med"},{"issue":"11","key":"1124_CR3","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/jci29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: Past, present, and future. J Clin Invest 116(11):2843\u20132854. https:\/\/doi.org\/10.1172\/jci29894","journal-title":"J Clin Invest"},{"issue":"2","key":"1124_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.28006","volume":"69","author":"E Rodrigues","year":"2024","unstructured":"Rodrigues E, Umeh E, Aishwarya, Navaratnarajah N, Cole A, Moy K (2024) Incidence and prevalence of myasthenia gravis in the United States: A claims-based analysis. Muscle Nerve 69(2):166\u2013171. https:\/\/doi.org\/10.1002\/mus.28006","journal-title":"Muscle Nerve"},{"issue":"2","key":"1124_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ (2018) Generalized myasthenia gravis: Classification, clinical presentation, natural history, and epidemiology. Neurol Clin 36(2):253\u2013260. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.002","journal-title":"Neurol Clin"},{"issue":"2","key":"1124_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149. https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"issue":"26","key":"1124_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia Gravis. N Engl J Med 375(26):2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"issue":"1","key":"1124_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM (2011) Myasthenic crisis. Neurohospitalist 1(1):16\u201322. https:\/\/doi.org\/10.1177\/1941875210382918","journal-title":"Neurohospitalist"},{"issue":"6","key":"1124_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","volume":"60","author":"RR Gummi","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R (2019) Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve 60(6):693\u2013699. https:\/\/doi.org\/10.1002\/mus.26689","journal-title":"Muscle Nerve"},{"key":"1124_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ (2019) Incidence, epidemiology, and transformation of ocular myasthenia gravis: A population-based study. Am J Ophthalmol 205:99\u2013105. https:\/\/doi.org\/10.1016\/j.ajo.2019.04.017","journal-title":"Am J Ophthalmol"},{"key":"1124_CR11","doi-asserted-by":"publisher","unstructured":"Kaminski HJ, Sikorski P, Coronel SI, Kusner LL (2024) Myasthenia gravis: the future is here. J Clin Invest 134(12). https:\/\/doi.org\/10.1172\/JCI179742","DOI":"10.1172\/JCI179742"},{"issue":"2","key":"1124_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s13760-023-02187-0","volume":"123","author":"R Mercelis","year":"2023","unstructured":"Mercelis R, Alonso-Jimenez A, Van Schil P (2023) Current management of myasthenia gravis in Belgium: a single-center experience. Acta Neurol Belg 123(2):375\u2013384. https:\/\/doi.org\/10.1007\/s13760-023-02187-0","journal-title":"Acta Neurol Belg"},{"issue":"3","key":"1124_CR13","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1007\/s00415-022-11458-4","volume":"270","author":"YN Kwon","year":"2023","unstructured":"Kwon YN, Woodhall M, Sung JJ, Kim KK, Lim YM, Kim H et al (2023) Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis. J Neurol 270(3):1478\u20131486. https:\/\/doi.org\/10.1007\/s00415-022-11458-4","journal-title":"J Neurol"},{"key":"1124_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","volume":"49","author":"F Romi","year":"2017","unstructured":"Romi F, Hong Y, Gilhus NE (2017) Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol 49:9\u201313. https:\/\/doi.org\/10.1016\/j.coi.2017.07.006","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"1124_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000328863","volume":"36","author":"F Pallaver","year":"2011","unstructured":"Pallaver F, Riviera AP, Piffer S, Ricciardi R, Roni R, Orrico D et al (2011) Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years. Neuroepidemiology 36(4):282\u2013287. https:\/\/doi.org\/10.1159\/000328863","journal-title":"Neuroepidemiology"},{"issue":"3","key":"1124_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/s-0037-1618591","volume":"49","author":"T Tozawa","year":"2018","unstructured":"Tozawa T, Nishimura A, Ueno T, Kaneda D, Miyanomae Y, Chiyonobu T et al (2018) A 5-Year Follow-Up of Triple-Seronegative Myasthenia Gravis Successfully Treated with Tacrolimus Therapy. Neuropediatrics 49(3):200\u2013203. https:\/\/doi.org\/10.1055\/s-0037-1618591","journal-title":"Neuropediatrics"},{"issue":"4","key":"1124_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/wnl.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I et al (2016) International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 87(4):419\u2013425. https:\/\/doi.org\/10.1212\/wnl.0000000000002790","journal-title":"Neurology"},{"key":"1124_CR18","unstructured":"Alexion, Pharmaceuticals (2025 Feb) Inc. Ultomiris (ravulizumab) [prescribing information]"},{"key":"1124_CR19","unstructured":"Alexion, Pharmaceuticals (2025 Feb) Inc. Soliris (eculizumab) [prescribing information]"},{"key":"1124_CR20","unstructured":"UCB I (2026 Jan) Zilbrysq (zilucoplan) [prescribing information]"},{"issue":"2","key":"1124_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s41669-022-00376-w","volume":"7","author":"RB McQueen","year":"2023","unstructured":"McQueen RB, Mendola ND, Jakab I, Bennett J, Nair KV, Nemeth B et al (2023) Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods. Pharmacoecon Open 7(2):217\u2013228. https:\/\/doi.org\/10.1007\/s41669-022-00376-w","journal-title":"Pharmacoecon Open"},{"issue":"2","key":"1124_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27992","volume":"69","author":"A Parthan","year":"2024","unstructured":"Parthan A, Royston M, Thanataveerat A, East EL, Parzynski CS, Habib AA (2024) Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States. Muscle Nerve 69(2):157\u2013165. https:\/\/doi.org\/10.1002\/mus.27992","journal-title":"Muscle Nerve"},{"issue":"1","key":"1124_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-022-02299-5","volume":"17","author":"G Yang","year":"2022","unstructured":"Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A (2022) The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis 17(1):163. https:\/\/doi.org\/10.1186\/s13023-022-02299-5","journal-title":"Orphanet J Rare Dis"},{"key":"1124_CR24","doi-asserted-by":"publisher","unstructured":"Lopez-Bastida J, Oliva-Moreno J, Linertova R, Serrano-Aguilar P (2016) Social\/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur J Health Econ 17(Suppl 1):1\u20135. https:\/\/doi.org\/10.1007\/s10198-016-0780-7","DOI":"10.1007\/s10198-016-0780-7"},{"issue":"10","key":"1124_CR25","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jval.2020.05.017","volume":"23","author":"BM Pennington","year":"2020","unstructured":"Pennington BM (2020) Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals. Value Health 23(10):1349\u20131357. https:\/\/doi.org\/10.1016\/j.jval.2020.05.017","journal-title":"Value Health"},{"key":"1124_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3389\/fpsyt.2018.00451","volume":"9","author":"Y Liu","year":"2018","unstructured":"Liu Y, Tang X (2018) Depressive Syndromes in Autoimmune Disorders of the Nervous System: Prevalence, Etiology, and Influence. Front Psychiatry 9:451. https:\/\/doi.org\/10.3389\/fpsyt.2018.00451","journal-title":"Front Psychiatry"},{"issue":"1","key":"1124_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C (2023) Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient\u2019s Perspective: A Qualitative Study. Neurol Ther 12(1):107\u2013128. https:\/\/doi.org\/10.1007\/s40120-022-00408-x","journal-title":"Neurol Ther"},{"issue":"2","key":"1124_CR28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K (2021) The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis. Neurol Ther 10(2):1103\u20131125. https:\/\/doi.org\/10.1007\/s40120-021-00285-w","journal-title":"Neurol Ther"},{"issue":"1","key":"1124_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40290-023-00509-4","volume":"38","author":"KA Ho","year":"2024","unstructured":"Ho KA, Pierce A, Stoltenberg M, Tarancon T, Mansfield C (2024) Eliciting Exploratory Patient Preference Data: A Case Study in a Rare Disease. Pharmaceut Med 38(1):55\u201362. https:\/\/doi.org\/10.1007\/s40290-023-00509-4","journal-title":"Pharmaceut Med"},{"issue":"6","key":"1124_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40271-022-00583-x","volume":"15","author":"EM Perfetto","year":"2022","unstructured":"Perfetto EM, Oehrlein EM, Love TR, Schoch S, Kennedy A, Bright J (2022) Patient-Centered Core Impact Sets: What They are and Why We Need Them. Patient 15(6):619\u2013627. https:\/\/doi.org\/10.1007\/s40271-022-00583-x","journal-title":"Patient"},{"issue":"5","key":"1124_CR31","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM (2011) MG-ADL: Still a relevant outcome measure. Muscle Nerve 44(5):727\u2013731. https:\/\/doi.org\/10.1002\/mus.22140","journal-title":"Muscle Nerve"},{"issue":"7","key":"1124_CR32","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52(7):1487\u20131489. https:\/\/doi.org\/10.1212\/wnl.52.7.1487","journal-title":"Neurology"},{"issue":"2","key":"1124_CR33","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study G (2008) Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 38(2):957\u2013963. https:\/\/doi.org\/10.1002\/mus.21053","journal-title":"Muscle Nerve"},{"issue":"1","key":"1124_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13023-025-03842-w","volume":"20","author":"S Dewilde","year":"2025","unstructured":"Dewilde S, Tollenaar NH, Boulanger P, Archer A, Pardo R, Cortes-Vicente E et al (2025) Caregiving burden among caregivers of people with myasthenia gravis. Orphanet J Rare Dis 20(1):311. https:\/\/doi.org\/10.1186\/s13023-025-03842-w","journal-title":"Orphanet J Rare Dis"},{"key":"1124_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00751-9","author":"C Reyes Acosta","year":"2025","unstructured":"Reyes Acosta C, Vlaev I, Rodriguez A, Foss A, Pinto A, Hewamadduma C et al (2025) What Patients Don\u2019t Say and Physicians Don\u2019t Ask: A Needs Assessment in Myasthenia Gravis Integrating Patient and Healthcare Professional Perspectives. Neurol Ther. https:\/\/doi.org\/10.1007\/s40120-025-00751-9","journal-title":"Neurol Ther"},{"issue":"6","key":"1124_CR36","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mus.26694","volume":"60","author":"L Harris","year":"2019","unstructured":"Harris L, Aban IB, Xin H, Cutter G (2019) Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis. Muscle Nerve 60(6):700\u2013706. https:\/\/doi.org\/10.1002\/mus.26694","journal-title":"Muscle Nerve"},{"issue":"4","key":"1124_CR37","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/mus.28063","volume":"69","author":"J Pesa","year":"2024","unstructured":"Pesa J, Choudhry Z, de Courcy J, Barlow S, Chatterton E, Thomas O et al (2024) The impact of myasthenia gravis severity on work and daily activities. Muscle Nerve 69(4):428\u2013439. https:\/\/doi.org\/10.1002\/mus.28063","journal-title":"Muscle Nerve"},{"key":"1124_CR38","doi-asserted-by":"publisher","first-page":"553626","DOI":"10.3389\/fneur.2020.553626","volume":"11","author":"P Szczudlik","year":"2020","unstructured":"Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A (2020) Determinants of Quality of Life in Myasthenia Gravis Patients. Front Neurol 11:553626. https:\/\/doi.org\/10.3389\/fneur.2020.553626","journal-title":"Front Neurol"},{"issue":"1","key":"1124_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10072-009-0167-y","volume":"31","author":"A Raggi","year":"2010","unstructured":"Raggi A, Leonardi M, Antozzi C, Confalonieri P, Maggi L, Cornelio F et al (2010) Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis. Neurol Sci 31(1):41\u201345. https:\/\/doi.org\/10.1007\/s10072-009-0167-y","journal-title":"Neurol Sci"},{"issue":"1","key":"1124_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/mus.26719","volume":"61","author":"MH Alanazy","year":"2020","unstructured":"Alanazy MH, Binabbad RS, Alromaih NI, Almansour RA, Alanazi SN, Alhamdi MF et al (2020) Severity and depression can impact quality of life in patients with myasthenia gravis. Muscle Nerve 61(1):69\u201373. https:\/\/doi.org\/10.1002\/mus.26719","journal-title":"Muscle Nerve"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01124-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01124-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01124-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:17:06Z","timestamp":1784913426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01124-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01124-y","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines and local regulations. The independent survey was reviewed by a central institutional review board (IRB) and determined to be exempt from IRB oversight.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PN has received research support from Alexion\/AstraZeneca Rare Disease, argenx (in progress) Cabeletta Bio (in process), Patient Centered Outcomes Research Institute; served on advisory boards and\/or consulted for Alexion\/AstraZeneca Rare Disease, Amgen, argenx, Cartesian, CVS, Dianthus, ImmuneAbs, Immunovant, Janssen, Serono, UCB, Viridian and VOR; serves\/served as Data Monitoring Committee Chair for argenx, NMD pharma and Sanofi; and receives royalties from Springer Nature. CT has nothing to disclose. JS is an employee of the EveryLife Foundation, which receives funding from the research sponsor for work unrelated to this research. SdR received grant funding from GSK, the National Institute of Mental Health (NIMH), the Patient-Centered Outcomes Research Institute (PCORI), and the Pharmaceutical Research Manufacturers of America (PhRMA) Foundation. CRamirez is cofounder and board treasurer for Own MG. AF is an employee of the Myasthenia Gravis Association, a member of the argenx Leadership Council, Rare Disease Connect in Neurology Steering Committee for UCB and has received consulting honoraria. NW, ACG, and EC are employees of Avalere, which received funding to conduct this research and consults with life sciences organizations. KSY is an employee of Alexion, AstraZeneca Rare Disease, holds stock or stock options in AstraZeneca, and holds stock in Takeda. MR was an employee of Alexion, Astrazeneca Rare Disease, at the time of analyses and holds stock or stock options in AstraZeneca. CRowe is an employee of Alexion, AstraZeneca Rare Disease, and holds stock or stock options in AstraZeneca. KGG has received honoraria from AcademicCME, Alexion, AstraZeneca Rare Disease, Amgen, argenx, Novartis, Springer, and UCB.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"126"}}